SCYNEXIS, Inc. Share Price
SCYXSCYNEXIS, Inc. Stock Performance
Open $0.95 | Prev. Close $0.86 | Circuit Range N/A |
Day Range $0.89 - $0.95 | Year Range $0.57 - $1.30 | Volume 2,021 |
Average Traded $0.93 |
SCYNEXIS, Inc. Share Price Chart
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
SCYNEXIS, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
16-Mar-26 | $0.95 | $0.90 | +0.00% |
16-Mar-26 | $0.95 | $0.90 | +4.40% |
13-Mar-26 | $0.86 | $0.86 | -3.36% |
12-Mar-26 | $0.87 | $0.89 | -0.89% |
11-Mar-26 | $0.87 | $0.90 | +0.00% |
10-Mar-26 | $0.85 | $0.90 | +5.25% |
09-Mar-26 | $0.82 | $0.86 | +5.80% |